The safety of therapeutic monoclonal antibodies: implications for cancer therapy including immuno-checkpoint inhibitors

Title:

The safety of therapeutic monoclonal antibodies: implications for cancer therapy including immuno-checkpoint inhibitors

Creator:

Demlova, R., Valík, D., Obermannova, R., and Zdražilová-Dubská, L.

Identifier:

https://cdk.lib.cas.cz/client/handle/uuid:a7e38e90-7fce-4748-8f55-eab50765dc40
uuid:a7e38e90-7fce-4748-8f55-eab50765dc40

Subject:

Camcer treatment, Monoclonal antibodies, Immune chceckpoint inhibitors, and Immune related adverse events

Type:

article, model:article, and TEXT

Description:

Monoclonal antibody-based treatment of cancer has been established as one of the most successful therapeutic strategies for both hematologic malignancies and solid tumors. In addition to targeting cancer antigens antibodies can also modulate immunological pathways that are critical to immune surveillance. Antibody therapy directed against several negative immunologic regulators (checkpoints) is demonstrating significant success in the past few years. Immune checkpoint inhibitors, ipilimumab, pembrolizumab and nivolumab, have shown significant clinical benefit in several malignancies and are already approved for advanced melanoma and squamous NSCLC. Based on their mechanism of action, these agents can exert toxicities that are unlike conventional cytotoxic chemotherapy, whose nature is close to autoimmune diseases - immune related adverse events (irAEs). In this review we focus on the spectrum of irAEs associated with immune checkpoint antibodies, discussing the pharmacological treatment strategy and possible clinical impact.

Language:

English

Rights:

http://creativecommons.org/publicdomain/mark/1.0/
policy:public

Source:

Physiological research | 2016 Volume:65 | Number:Suppl 4

Harvested from:

CDK

Metadata only:

false